• <pre id="bq1g9"><label id="bq1g9"></label></pre><pre id="bq1g9"></pre>
  • <td id="bq1g9"></td>
      <acronym id="bq1g9"></acronym>

        <td id="bq1g9"><ruby id="bq1g9"></ruby></td>

        <track id="bq1g9"><strike id="bq1g9"></strike></track>

        <tr id="bq1g9"><s id="bq1g9"></s></tr>

        <td id="bq1g9"><option id="bq1g9"></option></td>
      1. <p id="bq1g9"><ruby id="bq1g9"><menu id="bq1g9"></menu></ruby></p>
          <track id="bq1g9"><ruby id="bq1g9"><tt id="bq1g9"></tt></ruby></track>
          High-tech light
          High-tech light

          Development Path

          2023

          · HEC, an A-share listed company (600673.SH), Zunyi Municipal Government and GAC Group reached a strategic cooperation to improve the layout of the new energy industry
          · HEC Pharm R&D Center was restructured and renamed Sunshine Lake Pharma Co., Ltd. ("HEC Pharma")

          2022

          ·The construction of Zhejiang Dongyang base was started, with a total investment of 20 billion yuan
          ·Low-carbon high-end battery aluminum foil project started construction in Yichang, Hubei

          2021

          ·HEC Pharmaceutical Research Institute completed A round of financing of nearly 7 billion yuan
          ·HEC Pharmaceutical Research Institute completed the equity control of  HEC Changjiang Pharmaceutical (01558.HK), realizing the integration of pharmaceutical assets

          2020

          ·Mr. Zhang Yushuai took over as chairman of HEC Group and established a new board of directors of HEC Group. HEC officially entered the 2.0 new era of "co-creation, co-responsibility and sharing"
          ·HEC's first Class 1.1 original innovative drug "Emitasvir Phosphate" was approved for marketing

          2019

          The annual sales of anti-influenza drug Kewei reached nearly 7 billion yuan, setting a new high for similar anti-influenza drug products in China

          2018

          ·Cordyceps sinensis (breeding product) was included in "Guangdong Province Local Medicinal Materials Standard" (Volume 3)
          ·"Research on key technologies of Cordyceps sinensis breeding and its industrial application" won the first prize of Guangdong Science and Technology Progress Award

          2017

          The construction of the Ulanchap base in Inner Mongolia started with an investment of nearly 2 billion yuan

          2016

          HEC Health Research Institute was approved by the State Administration of Traditional Chinese Medicine to establish the "Key Research Laboratory of Cordyceps Sinensis Breeding and Product Research and Development"

          2015

          ·HEC Changjiang Pharmaceutical was listed on the main board of Hong Kong, stock code: 01558.HK
          ·HEC Pharmaceutical Research Institute is approved by the Ministry of Science and Technology of the People's Republic of China to establish a "State Key Laboratory of New Anti-infective Drug Research and Development"

          2014

          The construction of the Nyingchi base in Tibet began, which is a supporting base for the ecological breeding of Cordyceps sinensis

          2013

          A-share listed company HEC (600673.SH) issued additional private placements to expand the medium and high pressure formed foil project and the high specific volume corrosion foil project

          2012

          Took the lead in realizing the industrialization of Cordyceps sinensis ecological breeding in the world

          2011

          HEC's first generic drug approved by the U.S. FDA, Zidovudine Tablets for the treatment of AIDS, was on the market

          2010

          Shaoguan started the construction of pharmaceutical industry projects

          2009

          Provided oseltamivir phosphate reserve drug for the country's prevention and control of influenza epidemic, and commended by the National Development and Reform Commission

          2008

          Started the process of internationalization of preparations

          2007

          New electronic material assets were injected into A-share listed company HEC (600673.SH)

          2006

          Obtained the exclusive authorization of Roche's "Oseltamivir Phosphate"

          2005

          HEC a comprehensive and systematic research institute was established

          2004

          Zunyi Base in Guizhou  started construction

          2003

          ·HEC A-share backdoor listing, stock code: 600673.SH
          ·Dongguan Songshan Lake Factory started construction

          2002

          ·Guangdong Dongguan Base started construction
          ·Acquired Hubei Changhe Pharmaceutical Co., Ltd. and officially entered the pharmaceutical industry

          2001

          Yichang base in Hubei started construction

          2000

          "Low-voltage and high-volume formed foil" was included in the "Double High and One Excellent" project-oriented plan of the State Economic and Trade Commission's national key technological transformation

          1999

          HEC fully implemented the management of the general outline system, and the first edition of the "Outline of Work" was officially published and released

          1998

          The construction of Shaoguan base in Guangdong began, focusing on the development of electronic materials industry

          1997

          Mr. Zhang Zhongneng founded HEC Group
          亚洲 日韩 欧美 春色-亚洲精品国产第一综合99久久-亚洲人精品亚洲人成在线-白丝无内液液酱夹腿自慰
        1. <pre id="bq1g9"><label id="bq1g9"></label></pre><pre id="bq1g9"></pre>
        2. <td id="bq1g9"></td>
            <acronym id="bq1g9"></acronym>

              <td id="bq1g9"><ruby id="bq1g9"></ruby></td>

              <track id="bq1g9"><strike id="bq1g9"></strike></track>

              <tr id="bq1g9"><s id="bq1g9"></s></tr>

              <td id="bq1g9"><option id="bq1g9"></option></td>
            1. <p id="bq1g9"><ruby id="bq1g9"><menu id="bq1g9"></menu></ruby></p>
                <track id="bq1g9"><ruby id="bq1g9"><tt id="bq1g9"></tt></ruby></track>